27458481|t|A promising antitumor activity of evodiamine incorporated in hydroxypropyl-beta-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells.
27458481|a|BACKGROUND: Evodiamine has gained wide interests recently because of its antitumor activities. However, a superior bioavailability is required to achieve better efficacy due to its poor water solubility. The aim of this study was to enhance the evodiamine's aqueous solubility by preparing evodiamine/hydroxypropyl-beta-cyclodextrin (EVO/HP-beta-CD) inclusion complex, which is incorporated evodiamine into HP-beta-CD, and compare the antitumor activities before and after inclusion with HP-beta-CD in human hepatoma HepG2 cells. RESULTS: The EVO/HP-beta-CD inclusion complexes were prepared by the kneading method and structurally characterized. P-glycoprotein ATPase assays firstly demonstrated that evodiamine was a substrate of P-glycoprotein, while HP-beta-CD and EVO/HP-beta-CD inclusion complexes inhibited P-glycoprotein by blocking P-glycoprotein ATPase activity. The EVO/HP-beta-CD inclusion complexes may be a promising anticancer drug candidate without drug resistance. After given evodiamine or EVO/HP-beta-CD inclusion complexes intervention, cell viability evaluation indicated that the half inhibition concentration of evodiamine and EVO/HP-beta-CD inclusion complexes on HepG2 cells was 8.516 and 0.977 muM, respectively. The caspase-3 enzyme activity analysis and Annexin V/PI double-staining revealed that EVO/HP-beta-CD inclusion complexes possessed better antitumor activities than evodiamine. Additionally, Hoechst 33258 staining and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling assay demonstrated that EVO/HP-beta-CD inclusion complexes induced HepG2 cell apoptosis more effectively than evodiamine. CONCLUSIONS: The improved antitumor activities of evodiamine were attributed to the enhanced solubility and P-glycoprotein inhibition by HP-beta-CD. These results are promising for the drug administration of EVO/HP-beta-CD inclusion complexes to enhance the bioavailability of evodiamine in vivo.
27458481	34	44	evodiamine	Chemical	MESH:C049639
27458481	61	92	hydroxypropyl-beta-cyclodextrin	Chemical	MESH:D000073738
27458481	120	125	human	Species	9606
27458481	126	134	hepatoma	Disease	MESH:D006528
27458481	135	140	HepG2	CellLine	CVCL:0027
27458481	160	170	Evodiamine	Chemical	MESH:C049639
27458481	334	339	water	Chemical	MESH:D014867
27458481	393	403	evodiamine	Chemical	MESH:C049639
27458481	438	448	evodiamine	Chemical	MESH:C049639
27458481	449	480	hydroxypropyl-beta-cyclodextrin	Chemical	MESH:D000073738
27458481	482	485	EVO	Chemical	-
27458481	486	496	HP-beta-CD	Chemical	MESH:D000073738
27458481	539	549	evodiamine	Chemical	MESH:C049639
27458481	555	565	HP-beta-CD	Chemical	MESH:D000073738
27458481	636	646	HP-beta-CD	Chemical	MESH:D000073738
27458481	650	655	human	Species	9606
27458481	656	664	hepatoma	Disease	MESH:D006528
27458481	665	670	HepG2	CellLine	CVCL:0027
27458481	691	694	EVO	Chemical	-
27458481	695	705	HP-beta-CD	Chemical	MESH:D000073738
27458481	850	860	evodiamine	Chemical	MESH:C049639
27458481	880	894	P-glycoprotein	Gene	5243
27458481	902	912	HP-beta-CD	Chemical	MESH:D000073738
27458481	917	920	EVO	Chemical	-
27458481	921	931	HP-beta-CD	Chemical	MESH:D000073738
27458481	962	976	P-glycoprotein	Gene	5243
27458481	1025	1028	EVO	Chemical	-
27458481	1029	1039	HP-beta-CD	Chemical	MESH:D000073738
27458481	1142	1152	evodiamine	Chemical	MESH:C049639
27458481	1156	1159	EVO	Chemical	-
27458481	1160	1170	HP-beta-CD	Chemical	MESH:D000073738
27458481	1283	1293	evodiamine	Chemical	MESH:C049639
27458481	1298	1301	EVO	Chemical	-
27458481	1302	1312	HP-beta-CD	Chemical	MESH:D000073738
27458481	1336	1341	HepG2	CellLine	CVCL:0027
27458481	1391	1400	caspase-3	Gene	836
27458481	1430	1439	Annexin V	Gene	308
27458481	1473	1476	EVO	Chemical	-
27458481	1477	1487	HP-beta-CD	Chemical	MESH:D000073738
27458481	1551	1561	evodiamine	Chemical	MESH:C049639
27458481	1577	1590	Hoechst 33258	Chemical	MESH:D006690
27458481	1604	1641	terminal deoxynucleotidyl transferase	Gene	1791
27458481	1651	1655	dUTP	Chemical	MESH:C027078
27458481	1699	1702	EVO	Chemical	-
27458481	1703	1713	HP-beta-CD	Chemical	MESH:D000073738
27458481	1742	1747	HepG2	CellLine	CVCL:0027
27458481	1785	1795	evodiamine	Chemical	MESH:C049639
27458481	1847	1857	evodiamine	Chemical	MESH:C049639
27458481	1905	1919	P-glycoprotein	Gene	5243
27458481	1934	1944	HP-beta-CD	Chemical	MESH:D000073738
27458481	2005	2008	EVO	Chemical	-
27458481	2009	2019	HP-beta-CD	Chemical	MESH:D000073738
27458481	2074	2084	evodiamine	Chemical	MESH:C049639
27458481	Negative_Correlation	MESH:C049639	MESH:D006528
27458481	Association	MESH:C027078	1791
27458481	Association	MESH:C049639	5243
27458481	Positive_Correlation	MESH:D000073738	836
27458481	Association	MESH:C049639	MESH:D000073738
27458481	Association	MESH:D000073738	1791
27458481	Negative_Correlation	MESH:D000073738	5243

